2020 ASCO Virtual Direct™ Highlights

 

Breast
13:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Neoadjuvant Therapy in HR+ BC: Fulvestrant / Fulvestrant + Anastrozole vs. Anastrozole - Was There Significant Improvement of Endocrine-sensitive Disease Rate?

FEATURING Aditya Bardia
  • 306 views
  • July 8, 2020
  • 2
11:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Adjuvant Therapy in BC: Is There a Long-term Benefit of MammaPrint as Guidance for Chemo? Does Trastuzumab + Pertuzumab + Chemotherapy Remain SoC for High-risk HER2+ EBC?

FEATURING Aditya Bardia
  • 470 views
  • July 8, 2020
  • 2
04:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on MBC: Does Early Local Therapy Improve Survival in Patients With De Novo MBC and an Intact Primary Tumor?

FEATURING Aditya Bardia
  • 29 views
  • July 8, 2020
19:03

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ MBC: Comparing Efficacy of HER2 Kinase Inhibitors vs. Antibody Drug Conjugates vs. Immunomodulatory Agents

FEATURING Ian Krop
  • 570 views
  • July 13, 2020
  • 1
14:46

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on TNBC & HR+ MBC: Analysis & Comparison of 1st Line Options for PD-L1 +/- Cancers With(out) BRCA 1/2. Exploring the Optimal ET Agent to Combine With Palbociclib in the First-line Endocrine-sensitive Disease

FEATURING Ian Krop
  • 703 views
  • July 13, 2020
  • 4
12:59

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ Neoadjuvant BC: Which Pts Are Candidates for Preoperative Systemic Therapy in Early Stage Setting? Is Therapy With Anthracyclines Inevitable? How Can We Shorten Duration Trastuzumab?

FEATURING Reshma L. Mahtani
  • 19 views
  • July 13, 2020
15:17

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Adjuvant Therapy in HER2+ BC: Utilizing T-DM1 for Pts With Residual Disease vs. Extending Adjuvant Therapy With 1 yr of Neratinib vs. Adding Pertuzumab + SoC Trastuzumab - Which Option Provides Better Results?

FEATURING Reshma L. Mahtani
  • 21 views
  • July 13, 2020
09:30

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ MBC: Tucatinib vs. TD-M1 vs. Neratinib - Which Recently FDA Approved Agent Is the Best Option for Sequencing With Existing Therapies?

FEATURING Reshma L. Mahtani
  • 180 views
  • July 13, 2020
  • 1